NCT02166658 - A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

January 18, 2018

Conditions

Breast CancerLung CancerRecurrent Brain MetastasesProgressive Brain Metastases

Interventions

DRUG

Cabazitaxel

Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.

Trial Locations (1)

92637

Kliniken Nordoberpfalz, AG Klinikum Weiden, Medizinische Kliniken I, Weiden